Review Papers Against Their Own Results

Visual summary

Key numeric facts

• Sample: n=105 BRCA1/2‑negative early‑onset Pakistani breast cancer patients (67 ≤30y without family history; 38 ≤40y with family history) (Cohort & selection)
• Method: DHPLC scanning of full TP53 coding region then bidirectional DNA sequencing of variant fragments; DHPLC conditions from IARC TP53 resource; mutation positive controls used when available (Methods: DHPLC + sequencing)
• Result: 1 deleterious frameshift c.499_500delCA in exon 5 (predicted stop at codon 179) → prevalence 1% (95% CI 0.02–5.2%); nine other sequence variants (mostly known polymorphisms), two novel (a synonymous exon 8 c.903A>G predicted to affect splicing and a 3'UTR variant c.*144G>A) (Primary results)

Interpretation & critical appraisal (visual then bullet)

1. Strength — targeted, rigorous detection: Full coding-region DHPLC + confirmatory Sanger sequencing is an appropriate and sensitive approach for single-nucleotide and small indel detection; authors used IARC-recommended primers/conditions and mutation-positive controls when available (Method robustness).
2. Limitation — sample size and precision: n=105 yields wide CI for low-prevalence events; observing 1/105 gives limited precision (95% CI spans ~0.02–5.2%). A larger population-based series would narrow CI and better define prevalence (authors note this) (Sample-size limitation).
3. Limitation — incomplete mutation space: Study did not assay non‑coding regulatory regions nor perform copy-number/large-rearrangement testing (authors cite large genomic rearrangements may account for ~5–10% of TP53 events). Thus the reported prevalence is for coding‑sequence small variants only (Unscreened mutation classes).
4. Selection & survivorship bias: Cohort derived from patients who underwent BRCA testing; selection may enrich for certain clinical features and could exclude rapidly fatal TP53 carriers (authors discuss but judge unlikely as 85% samples drawn within 12 months of diagnosis) (Selection & survivorship).
5. External generalizability: Study mainly Punjabi Pakistani participants; authors state single ethnic group yields internal uniformity but reduces generalizability to other Pakistani subpopulations or South Asian groups (Population specificity).
6. Functional assessment of variants: The novel synonymous c.903A>G was assessed in silico for ESE motif loss and codon usage change (DRSCU -0.66), supporting possible splicing/translation effects, but no RNA/protein functional validation was performed — so that variant remains uncertain (In silico variant assessment).

What the paper adds to the field

• Provides the first TPM53 germline screening series focused on early-onset breast cancer in Pakistani women, showing low coding‑region TP53 mutation prevalence (1%). This contributes population‑specific data where prior South/SE Asian data were sparse (Population-specific contribution).

Where the conclusion could be overturned (falsification scenarios)

1. Large, population-based sequencing (including copy-number and non‑coding regulatory regions) in >1,000 comparable Pakistani early‑onset patients detects substantially higher TP53 pathogenic variant frequency (e.g., ≥3–5%).
2. Functional assays show the novel synonymous or 3'UTR variants are pathogenic and occur at appreciable frequency in cases vs controls, increasing TP53 contribution.
3. Founder or population‑specific recurrent TP53 variants are discovered in other Pakistani subgroups not sampled here.

Practical recommendation (evidence-weighted)

Given the low observed prevalence (1%) and limited power, routine TP53 germline screening for all BRCA1/2‑negative early‑onset Pakistani breast cancer patients is not supported by these data alone — targeted testing remains most efficient for pedigrees meeting LFS/LFL criteria or where tumor types in the family suggest TP53 involvement. This follows the authors' conclusion and acknowledges the sample/assay limits (Authors).

Short list of high-value follow-up experiments (practical & falsifying)

• Perform targeted capture + high-depth NGS (including intronic, promoter, 3'UTR regions) and MLPA/array-CGH for large rearrangements in a larger (≥1,000) early-onset Pakistani cohort to estimate true TP53 pathogenic variant prevalence.
• Functionally test the c.903A>G synonymous and c.*144G>A 3'UTR variants with minigene splicing assays and reporter assays for mRNA stability/translation to confirm predicted effects.
• Establish family segregation (parental DNA) for the c.499_500delCA carrier and screen extended family members to determine inheritance and penetrance in this pedigree.

Primary citation:

Rashid et al., Familial Cancer 2012